{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:52Z","timestamp":1790272192390,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T00:00:00Z","timestamp":1317168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12012-011-9146-7","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T01:49:28Z","timestamp":1317088168000},"page":"184-187","source":"Crossref","is-referenced-by-count":29,"title":["Bortezomib-Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma"],"prefix":"10.1007","volume":"12","author":[{"given":"Ajay","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvita","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,28]]},"reference":[{"key":"9146_CR1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1359-6446(03)02647-3","volume":"8","author":"J Adams","year":"2003","unstructured":"Adams, J. (2003). Potential for proteasome inhibition in the treatment of cancer. Drug Discovery Today Biosilico, 8, 307\u2013315.","journal-title":"Drug Discovery Today Biosilico"},{"key":"9146_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1959","volume":"5","author":"I Sanchez-Serrano","year":"2006","unstructured":"Sanchez-Serrano, I. (2006). Success in translational research: lessons from the development of bortezomib. Nature Reviews Drug Discovery, 5, 107\u2013114.","journal-title":"Nature Reviews Drug Discovery"},{"key":"9146_CR3","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S Lonial","year":"2005","unstructured":"Lonial, S., Waller, E. K., Richardson, P. G., et al. (2005). Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 106, 3777\u20133784.","journal-title":"Blood"},{"key":"9146_CR4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008). Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593\u20131599.","journal-title":"Blood"},{"key":"9146_CR5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","volume":"138","author":"O Enrico","year":"2007","unstructured":"Enrico, O., Gabriele, B., Nadia, C., Sara, G., Daniele, V., Giulia, C., et al. (2007). Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal Haematology, 138, 396\u2013397.","journal-title":"British Journal Haematology"},{"key":"9146_CR6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2407-6-129","volume":"6","author":"J Voortman","year":"2006","unstructured":"Voortman, J., & Giaccone, G. (2006). Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a nonsmall cell lung cancer patient: a case report. BMC Cancer, 6, 129.","journal-title":"BMC Cancer"},{"key":"9146_CR7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-06-1812","volume":"13","author":"JR Berenson","year":"2007","unstructured":"Berenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B., & Yeh, H. S. (2007). A phase I\/II study of arsenic trioxide\/bortezomib\/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Research, 13, 1762\u20131768.","journal-title":"Clinical Cancer Research"},{"key":"9146_CR8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12185-008-0139-7","volume":"88","author":"A Hacihanefioglu","year":"2008","unstructured":"Hacihanefioglu, A., Tarkun, P., & Gonullu, E. (2008). Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. International Journal of Hematology, 88, 219\u2013222.","journal-title":"International Journal of Hematology"},{"key":"9146_CR9","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12185-010-0586-9","volume":"91","author":"H Takamatsu","year":"2010","unstructured":"Takamatsu, H., Yamashita, T., Kotani, T., Sawazaki, A., Okumura, H., & Nakao, S. (2010). Ischemic heart disease associated with bortezomib treatment combined with dexamehtasone in a patient with multiple myeloma. International Journal of Hematology, 91, 903\u2013906.","journal-title":"International Journal of Hematology"},{"key":"9146_CR10","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.ATV.0000232501.08576.73","volume":"26","author":"D Versari","year":"2006","unstructured":"Versari, D., Herrmann, J., Gossl, M., Mannheim, D., Sattler, K., Meyer, F. B., et al. (2006). Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2132\u20132139.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9146_CR11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.fjc.0000175240.64444.68","volume":"46","author":"G Jancso","year":"2005","unstructured":"Jancso, G., Cserepes, B., Gasz, B., Benko, L., Ferencz, A., Borsiczky, B., et al. (2005). Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium. Journal of Cardiovascular Pharmacology, 46, 295\u2013301.","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"9146_CR12","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","volume":"176","author":"D Nowis","year":"2010","unstructured":"Nowis, D., Maczewski, M., Mackieewicz, U., Kujawa, M., Ratajska, A., Wiekowski, M. R., et al. (2010). Cardiotoxicity of the anticancer therapeutic agent bortezomib. American Journal of Pathology, 176, 2658\u20132668.","journal-title":"American Journal of Pathology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-011-9146-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-011-9146-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-011-9146-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T21:40:22Z","timestamp":1559425222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-011-9146-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,28]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9146"],"URL":"https:\/\/doi.org\/10.1007\/s12012-011-9146-7","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,28]]}}}